Draft:Genetron Health

Genetron Health Enters into Platform Partnership with World Economic Forum

Retrieved on: 
Friday, July 2, 2021
Davos, World Economic Forum, Organizations, Articles, Draft:Genetron Health

BEIJING, July 02, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform.

Key Points: 
  • BEIJING, July 02, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform.
  • Genetron Health, as a platform partner, will contribute its research insights, technologies, and industry experience to future projects with the WEF through the Platform of Shaping the Future of Health and Healthcare .
  • Together, Genetron Health and the WEF will work to drive more impact and action in the global healthcare industry.
  • Through participating in the WEFs past dialogues and research projects, Genetron Health has found that the WEFs Health and Healthcare Platform shares many of its values and goals.

Genetron Health Releases 16 New Research Results at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Cancer, Oncology, Draft:Genetron Health

BEIJING, June 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 16 research results at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • BEIJING, June 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 16 research results at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • The results were from studies that Genetron Health conducted in partnership with 16 leading hospitals in China.
  • These studies analyzed nearly 10 different types of high-incidence cancers, covering lung cancer, bladder cancer, and thyroid cancer.
  • For example, the research on genetic factors of lung cancer may help doctors to prevent or diagnose lung cancer at an earlier stage.

Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer

Retrieved on: 
Thursday, May 13, 2021
Oncology, Health, Hospitals, General Health, Clinical trials, Research, Science, Cancer, Siemens Healthineers, Targeted therapy, Oncology, Lung cancer, Health, Medicine, Draft:Genetron Health, Genetron Holdings Limited, Siemens Healthineers AG, GENETRON HOLDINGS LIMITED, SIEMENS HEALTHINEERS AG

\xe2\x80\x9cWe are pleased to collaborate with Siemens Healthineers for our S5 instrument and lung 8 IVD assay, which helps diagnose and treat cancer patients.

Key Points: 
  • \xe2\x80\x9cWe are pleased to collaborate with Siemens Healthineers for our S5 instrument and lung 8 IVD assay, which helps diagnose and treat cancer patients.
  • We are excited to forge a strategic partnership with Genetron Health, an industry leading precision oncology platform company.
  • In China, 787,000 cases of lung cancer are diagnosed every year, with about 631,000 deaths [1] caused annually as well.
  • As the "first step" of targeted therapy for lung cancer, cancer molecular gene detection is the key to guided clinical treatment and drug applications.

Genetron Health to Present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit

Retrieved on: 
Thursday, April 1, 2021
SVB Leerink, Evidence-based medicine, Precision medicine, Draft:Genetron Health

BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021.

Key Points: 
  • BEIJING, April 01, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the SVB Leerink CybeRx Series: Liquid Biopsy & Oncology Dx Summit on Wednesday April 7th, 2021.
  • Interested parties may request more information by contacting their sales representative at SVB Leerink.
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
  • Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.

Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar

Retrieved on: 
Thursday, April 1, 2021
Biotechnology, Health, Science, Research, Oncology, Medicine, Clinical medicine, Branches of biology, Cancer screening, DNA, Circulating free DNA, Medical signs, Biotechnology, Liquid biopsy, Biopsy, Biomarker, Draft:Genetron Health

Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH) sponsored a Science/AAAS Webinar, Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment, which launched today.

Key Points: 
  • Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH) sponsored a Science/AAAS Webinar, Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment, which launched today.
  • During the panel discussion, Genetron Healths Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled Profiling cfDNA-based Biomarkers for the Early Detection of Cancer.
  • He also outlined the development and features of the Companys proprietary early screening technology, Mutation Capsule; presented a multi-center prospective study that adopted the Companys liquid biopsy-based early screening test, HCCscreenTM; and explained potential R&D pathway for pan-cancer screening assay.
  • She also emphasized the advantages of liquid biopsy technology in cancer screening, and the benefits of blood tests in particular.

Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China

Retrieved on: 
Wednesday, March 24, 2021
Biotechnology, Health, Oncology, Medical devices, Draft:Genetron Health, Hepatology, Liver cancer, Cancer, Precision medicine, HCCscreenTM and Liver Cancer, Genetron Holdings Limited

In September 2020, Genetron Health received the U.S. Food and Drug Administration (FDA)s Breakthrough Device designation for HCCscreenTM, and the product has been commercialized recently as a lab developed test (LDT) in China.

Key Points: 
  • In September 2020, Genetron Health received the U.S. Food and Drug Administration (FDA)s Breakthrough Device designation for HCCscreenTM, and the product has been commercialized recently as a lab developed test (LDT) in China.
  • Globally, liver cancer is the fourth most common cause of cancer-related death and the sixth in terms of incidence1.
  • Market data by Frost and Sullivan estimated that as of 2019, among the 120 million high risk liver cancer population in China, around 74 million were HBV carriers.
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.

Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26th, 2021

Retrieved on: 
Wednesday, March 17, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Companies, Credit Suisse, Precision medicine, Finance, Banks, Draft:Genetron Health

Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on Mar.

Key Points: 
  • Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on Mar.
  • Sizhen Wang, co-founder and Chief Executive Officer, will also attend a fireside chat at 3:00 pm Beijing time (3:00 am ET).
  • Interested parties may request more information by contacting their sales representative at Credit Suisse.
  • Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.

Genetron Health to Present at Science/AAAS Webinar About Early Cancer Screening on March 31

Retrieved on: 
Monday, March 15, 2021
Biotechnology, Health, Stem cells, Pharmaceutical, Oncology, Medicine, Clinical medicine, Cancer screening, DNA, Circulating free DNA, Medical tests, Screening, Liquid biopsy, Cancer, Oncology, Biopsy, Draft:Genetron Health

Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the company will present at one of the Science/AAAS Webinar Series, Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment.

Key Points: 
  • Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the company will present at one of the Science/AAAS Webinar Series, Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment.
  • Early detection of a cancer is critical to its characterization, treatment, and eventual elimination.
  • Many cancers, however, grow undetected due to the traditional lack of sufficiently accurate or sensitive means to detect them.
  • This webinar will discuss these advances in early cancer screening, such as recent successes and new methodologies for cfDNA detection and analysis.

Genetron Health to Release Thirteen Research Findings at 21st World Conference on Lung Cancer

Retrieved on: 
Wednesday, January 27, 2021
Oncology, Health, Genetics, General Health, Pharmaceutical, Biotechnology, Branches of biology, Medical genetics, Biotechnology, Oncogenomics, Lung cancer, Biology, Life sciences, Draft:Genetron Health

Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will release thirteen new research findings at the 21st World Conference on Lung Cancer (WCLC), which will be held virtually from January 28 to 31.

Key Points: 
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will release thirteen new research findings at the 21st World Conference on Lung Cancer (WCLC), which will be held virtually from January 28 to 31.
  • Genetron Health joined hands with eight top Chinese hospitals to conduct in-depth analysis and research on a large-scale lung cancer cohort, leveraging the Genetron One-Step Seq Method and core products such as Onco PanscanTM.
  • The thirteen research findings we are releasing at the WCLC, which focus on the characteristics of the Chinese lung cancer population, have made discoveries in multiple dimensions and demonstrated Genetron Healths strong capabilities in the fundamental research of lung cancer genomics, said Dr. Hai Yan, Co-founder and Chief Scientific Officer of Genetron Health.
  • In addition, the rare cases detected through Genetron Healths patented research technology will draw more attention to and promote further research on relevant cancer diagnosis and treatment."

Genetron Health to Present at BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021

Retrieved on: 
Wednesday, January 13, 2021
Research, FDA, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Evidence-based medicine, Precision medicine, Systems biology, Draft:Genetron Health

Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021.

Key Points: 
  • Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present at the BTIG Early Cancer Screening, Diagnostics Reimbursement and Genomic Tools KOL Day on Jan. 22, 2021.
  • Genetron Holdings Limited (Genetron Health or the Company) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
  • Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
  • Further information regarding these and other risks, uncertainties or factors is included in the Companys filings with the SEC.